Abstract. Exogenous overexpression of hRFI, originally isolated in our laboratory, inhibits not only death receptormediated apoptosis but also the mitochondrial apoptosis induced by several chemotherapeutic agents including 5-fluorouracil (5-FU). Recently, it has become clear that hRFI targets and degradates caspase-8 and -10 in death receptormediated apoptosis by E3 ubiquitin activity in a ring finger domain homologous to that of X-chromosome-linked inhibitor of apoptosis protein (XIAP). However, the cellular mechanism of the inhibition of mitochondrial apoptosis by hRFI has not been fully elucidated. We prepared HCT116 overexpressing hRFI (HCT116/hRFI) cells and comprehensively analyzed the expression changes of 51 apoptosis-related genes with or without 5-FU treatment between HCT116/hRFI and mock cells using microfluidic low-density arrays. As a result, we identified four genes (Bcl-2, Bcl-XL, cIAP2, and CFLAR) whose expression was four or more times higher in HCT116/ hRFI cells than in HCT116/LacZ cells, and found that Bcl-2 and the ratio of Bcl-2/Bax or Bcl-2/Bak were upregulated when HCT116/hRFI cells were treated with 5-FU. Furthermore, we also validated the up-regulation of Bcl-2 and Bcl-XL in HCT116/hRFI cells treated with 5-FU by Western blot analysis. Such evidence suggests that the modulation of Bcl-2 family proteins seen in 5-FU treatment plays an important role in the anti-apoptotic function of HCT116/hRFI cells.
Introduction
hRFI (accession no. AB084914), human ring finger homologous to IAP type, is a gene which we isolated by means of a two-hybrid yeast screening method using hTID-1, an apoptosis regulator protein, as bait (1) (2) (3) and subsequently determined the cellular and chromosomal localization. We also demonstrated that hRFI is preferentially expressed in several digestive tract cancers, such as of the esophagus (1), stomach (4) , and colorectum (5) . Especially in colorectal carcinogenesis, the expression of hRFI increases in the transition from the normal colorectal mucosa to adenoma, and from adenoma to carcinoma (5) . From the structural point of view, hRFI has several functional domains, including a ring finger domain highly homologous to that of X-chromosome-linked inhibitor of apoptosis protein (XIAP) (1) , which is the most potent inhibitor of apoptosis among the IAPs (6, 7) , and a phospholipid-binding FYVE domain (8) .
Recently, it has been reported that the ring finger domain has E3 ubiquitin activity which targets caspase-8 and -10 in death receptor-mediated apoptosis (8) , supporting our previous finding that exogenous overexpression of hRFI in colorectal cancer cells results in inhibition of the extrinsic apoptotic pathway (9) . However, we found that exogenous overexpression of hRFI inhibited not only death receptormediated apoptosis but also the mitochondrial apoptosis induced by several chemotherapeutic agents, including 5-fluorouracil (5-FU) (10) . The cellular mechanism of the inhibition of mitochondrial apoptosis by hRFI has not been established yet. Considering that resistance to the induction of apoptosis is one of the most important determinants of colorectal cancer cell chemoresistance to 5-FU (11, 12) , clarification of this mechanism is an important issue for strategic chemotherapy applications in colorectal cancer patients.
To identify the differentially expressed genes in HCT116 cells overexpressing hRFI and mock cells with or without 5-FU treatment, we screened 51 apotosis-related genes by microfluidic low-density arrays. A stable HCT116 cancer cell line consistently overexpressing the hRFI protein was established as described previously (9) . In brief, the full-length cDNA of hRFI was subcloned into a pcDNA3.1/V5-His vector (Invitrogen), and HCT116 cells were transfected with 2 μg/ml plasmids using 5 μg/ml lipofectin (Invitrogen) in serum-free OPTIMEM medium (Invitrogen) according to the manufacturer's protocol. For stable transfection, cells were trypsinized and incubated in the presence of 1000 μg/ml G418 (BD Biosciences, Palo Alto, CA) for 2-3 weeks. Individual G418 resistant colonies were isolated and maintained in the presence of G418.
Materials and methods

Establishment
Preparation of mRNA and whole lysate of samples. HCT116 cells overexpressing hRFI (HCT116/hRFI) and mock (HCT116/ LacZ) cells were plated in 10-cm culture dishes at a density of 2x10 6 /dish. Twenty-four hours after plating, two dishes of each cell were subjected to isolation of mRNA and whole lysate as the no 5-FU treatment. For others, 1 or 5 μg/ml of 5-FU was added. Cells harvested at 24 and 48 h after the treatment were also subjected to mRNA and cell lysate preparation. To isolate mRNA, we used Isogen (Nippongene) according to the manufacturer's protocol. To isolate whole lysate for Western blotting, cells were scraped and lysed for 1 h at 4˚C in a lysis buffer containing phosphate buffered saline (PBS) with 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.01 mg/ml aprotinin and 0.01 mg/ml leupeptin. Cell lysates were cleared by centrifugation. The concentration of proteins was determined using BCA protein assay reagent (Pierce Biomedical Company, Rockford, IL).
Western blotting. Aliquots (40 μg) of whole cell lysates were electrophoresed in 15% Ready Gel J (Bio-Rad, Hercules, CA). Separated proteins were electrophoretically transferred to a Hybond ECL nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, England) and incubated with each antibody. Proteins were detected and visualized using an ECL detection system (Amersham Pharmacia Biotech). A mouse anti-V5 monoclonal antibody was purchased from Invitrogen; a mouse anti-ß-actin monoclonal antibody from Sigma; a mouse anti-Bak monoclonal antibody from BD Biosciences (San Diego, CA); a mouse anti-Bax, Bcl-XL monoclonal antibody from Santa Cruz Biotechnology (Santa Cruz, CA); and a mouse anti-Bcl-2 monoclonal antibody from Dako Cytomation Denmark A/S (Glostrup, Denmark).
Microfluidic low-density arrays. We selected 51 apotosisrelated genes from the source of European Bioinformatics Institute (EBI) GeneOntology. The categories used for the selection are as follows; apoptosis activator activity (GO: 0016506), apoptosis inhibitor activity (GO:0008189), and apotosis regulator activity (GO:0016329). For 51 selected genes as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), we ordered microfluidic low-density arrays from Applied Biosystems. The detectors for each gene used in this study are shown in Table I . The observed Ct values of genes were normalized by the ¢¢Ct methods, using the GAPDH gene as an endogenous control and mock cell lines as calibrator samples (13, 14) .
Results
Identification of differentially expressed apotosis-related genes according to hRFI expression. The analysis of the fold change of gene expression between HCT116/hRFI and HCT116/LacZ cells using microfluidic low-density arrays identified 4 genes (Bcl-2, Bcl-XL, cIAP2, and CFLAR) whose expression levels were four or more times higher in HCT116/hRFI cells than in HCT116/LacZ cells ( Table I) .
Analysis of the fold change of the ratio of gene expression at 48 h to that at 24 h treatment with 5-FU.
When cells were treated with 1 μg/ml or 5 μg/ml of 5-FU, the fold change of the ratio of gene expression at 48 h to that at 24 h exhibited the highest level in Bcl-2 (14.118 and 7.393, respectively). Survivin and TNFRSF6 also exhibited remarkably high fold changes. Compared to Bcl-2, Bcl-XL exhibited small changes (1.187 and 1.386, respectively). The results are shown in Table I .
Evaluation of the ratio of expression of anti-apoptotic genes to that of pro-apoptotic genes.
We analyzed the expression ratio of Bcl-2 to Bax, Bcl-2 to Bak, Bcl-XL to Bax, and Bcl-XL to Bak. The fold change of the ratio at 48 h of 5-FU treatment to that at 24 h exhibited a high level in Bcl-2 to Bax and Bcl-2 to Bak, as shown in Table II . Especially when treated with 1 μg/ml of 5-FU, the fold change was remarkably high in these ratios (8.134 and 8.944, respectively). In contrast, the fold change in Bcl-XL to Bax and Bcl-XL to Bak was low.
Western blot analysis. Western blot analysis revealed that the expression of Bcl-XL in HCT116/hRFI cells was much higher than that in HCT116/LacZ cells; however, there was no remarkable alteration in the expression of other proteins (Bcl-2, Bax, and Bak) between the two cell lines. When cells were treated with 5-FU at concentrations of 1, and 5 μg/ml for 24 h, Bcl-XL was remarkably induced only in HCT116/ hRFI cells.
Bcl-2 was gradually induced in a time-dependent manner after treatment with 1 μg/ml of 5-FU; however, the induction of Bcl-2 reached the highest level after 24 h treatment with 5 μg/ml of 5-FU and its expression decreased after 48 h treatment. Exogenous hRFI detected with anti-V5 antibody, like Bcl-XL, was induced in HCT116/hRFI cells. In contrast, the expression of pro-apoptotic proteins, Bax and Bak, exhibited no remarkable alteration in either cell line (Fig. 1) .
Discussion
Fluoropyrimidines, including 5-fluorouracil (FU), are the most common drugs used for the treatment of colorectal cancer, and prediction of the response to 5-FU at the molecular level is very important in effective clinical use. Previously, we reported that overexpression of hRFI significantly inhibited several chemotherapeutic agents, including 5-FU, with decreased activities of caspase-3, -8, and -9 (10). Furthermore, we found that high expression of hRFI correlated with resistance to Table I . Fold change of 51 apotosis-related genes' expression with or without 5-FU treatment between HCT116/hRFI and HCT116/LacZ cells.
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needs to be elucidated. Hence, we decided to comprehensively analyze 51 apoptosis-related genes which were selected from EBI GeneOntology and investigated by means of microfluidic low-density arrays. The microfluidic low-density array was developed by Applied Biosystems (Foster City, CA, USA), and mRNA expression of up to 384 target genes can be analyzed on a single card on the basis of real-time reverse transcription PCR (RT-PCR). The target genes can be randomly selected and researchers can utilize this method as a custom-made DNA microarray. Abruzzo LV et al have described the practical procedures of this method and reported reproducible analysis with a wide dynamic range compared to other high-throughput forms of analysis (14) . As a result of the study of the 51 apoptosis-related genes' expression between HCT116/hRFI and HCT116/LacZ cells, we identified 4 genes (Bcl-2, Bcl-XL, cIAP2, and CFLAR) whose expression is four or more times higher in HCT116/ hRFI cells than in HCT116/LacZ cells. Bcl-2 and Bcl-XL are the anti-apoptotic members of the Bcl-2 family, sharing the conserved Bcl-2 homology (BH) regions BH1, BH2 and BH3 (7, 16, 17) , and act as stabilizers of mitochondrial membrane integrity by blocking the release of cytochrome c (and smac/ DIABLO) and subsequent caspase-9 and -3 activation, thus regulating the mitochondrial apoptotic pathway (7, 18, 19) . cIAP2 is also known as HIAP1, one of the inhibitors of apoptosis protein (IAP), and inhibits apoptosis by binding to the tumor necrosis factor receptor-associated factors, TRAF1 and TRAF2 (20, 21) . CFLAR has several nomenclature designations (FLIP, CASPER, FLAME1, CASH, CLARP, and MRIT), interacts with FADD, TRAF1, caspase-8, and -3 and regulates cell death pathways (22, 23) . It is of great interest that the expression of these genes, which mainly exert inhibition of apoptosis, was higher in HCT116/hRFI than in HCT116/LacZ cells. Furthermore, the analysis of the fold change of each gene's expression between the two cell lines, not only in periods of quiescence but also in the time course after treatment with 5-FU, helps shed light on the cellular mechanisms of the antiapoptotic effects of hRFI. Our previous report revealed that HCT116/hRFI cells significantly inhibited 5-FU-induced apoptosis compared to HCT116/LacZ cells after treatment with 5-FU at 0.3, 1, and 3 μg/ml for 48 h (10) . Hence, we analyzed the expression of genes for HCT116/hRFI and HCT116/LacZ cells with or without treatment of 5-FU at 1 and 5 μg/ml for 48 h. When treated with 5-FU, the fold change of the ratio of gene expression at 48 h to that at 24 h was the highest in Bcl-2. Survivin and TNFRSF6 also exhibited remarkably high changes. Unlike Bcl-2, Bcl-XL didn't exhibit remarkable alterations of fold change of the ratio (at 48 h:24 h) between the two cell lines. This evidence suggests that upregulation of Bcl-2 may have an effect on the anti-apoptotic function of hRFI during treatment 5-FU.
Recently, there have been reports that a dynamic interplay among the Bcl-2 family of proteins has an effect on the response to some chemotherapeutic agents. In particular, the relative ratio of anti-apoptotic (Bcl-2 or Bcl-XL) to proapoptotic (Bax or Bak) genes is one of the determinants of the response to DNA-damaging agents and 5-FU (11, (24) (25) (26) . We also previously reported that the Bcl-XL to Bax ratio significantly correlates with resistance to 5-FU in colorectal cancer cell lines (26) . Hence, we analyzed four kinds of ratio change (Bcl-2:Bax, Bcl-2:Bak, Bcl-XL:Bax, and Bcl-XL: Bak) during 5-FU treatment. As shown in Table II , we found that the fold change of the ratio at 48 h to that at 24 h treatment of 5-FU at a concentration of 1 μg/ml was high in Bcl-2 to Bax and Bcl-2 to Bak. Especially when treated with 1 μg/ml of 5-FU, the fold change was remarkably high among these ratios (8.134 and 8.944, respectively). The expression of Bcl-2 family genes in a steady-state varies extremely widely in colorectal cancer cell lines, as has been reported previously (26) . Which genes are predominantly induced or suppressed by 5-FU treatment apparently also varies in different cells; however, it is suggested in this study that the expression of pro-or anti-apoptotic genes belonging to the Bcl-2 family generally have the greatest effect on 5-FU chemosensitivity.
Finally, we performed Western blot analysis to validate the change of expression at protein level. Western blotting revealed that, after treatment with 5-FU at concentrations of 1 and 5 μg/ml for 24 h, Bcl-XL was remarkably induced in HCT116/hRFI cells, and that Bcl-2 was gradually induced in a time-dependent manner after treatment with 1 μg/ml of 5-FU. These results imply that Bcl-XL is initially upregulated and, ONCOLOGY REPORTS 15: 1293 -1298 , 2006 Table II. The fold change of the expression ratio of Bcl-2 to Bax, Bcl-2 to Bak, Bcl-XL to Bax, and Bcl-XL to Bak when treated with 5-FU. ----------------------------------------------- later, Bcl-2 is gradually upregulated when apoptosis is induced by 5-FU treatment in hRFI overexpressing cells and that such upregulation of anti-apoptotic genes might play an important role in the anti-apoptotic function of hRFI for 5-FU induced apoptosis. Recently, McDonald ER et al reported two genes which bind to and negatively regulate death effector domain (DED) caspases (caspase-8 and -10) by ubiquitination (8) . Interestingly, one of these, CARP1, is hRFI itself, and they clarified that hRFI (CARP1 in their terminology) has E3 activity via a ring finger domain at the C terminus, leading to the proteasomal degradation of DED caspases when hRFI is overexpressed. This finding supports our previous data that overexpression of hRFI inhibits apoptosis induced by tumor necrosis factor-· (TNF-·) or TNF-related apotosis-inducing ligand (TRAIL) in colorectal cancer cells (9) , and might account for the cellular mechanism of inhibition of death receptor-mediated apoptosis by hRFI. Considering the mechanism in mitochondrial apoptotic pathway, there is the possibility that hRFI regulates certain apoptosis activating proteins through proteasomal degradation by its E3 activity. This might also clarify hRFI overexpression and the manner in which hRFI upregulates Bcl-2 and Bcl-XL and elevates the relative ratio of Bcl-2 to Bax or to Bak during 5-FU treatment.
